GigCapital (GIG) Extends Rights Tender Offer to Nov. 22nd
by Kristi Marvin on 2019-11-07 at 5:13pm

GigCapital, Inc. (GIG), announced this afternoon that it will be extending its Tender Offer to purchase up to 14,873,256 of its outstanding Rights until one minute past 11:59 p.m., New York City time, on November 22, 2019, unless further extended or terminated. The tender offer was previously scheduled to expire today, at one minute past 11:59 p.m., New York City time.  However, as of today, only 1,826,233 of the 14,873,256 Rights outstanding (which includes the 498,256 Rights included in the Founders Units) have been tendered.

The purchase price for the Rights remains $0.99 per Right, but without any additional incentive (or higher price) it’s unlikely a significant number of additional Rights holders will tender through the new deadline.  However, keep in mind, Gig has rounded up multiple Rights arrangements via Greenhaven, Kepos, and Yakira, whereby they agreed not to sell the shares underlying the Rights they own, as well as any additional Rights they were able to purchase. We don’t know yet how many Rights each of them were able to buy, but the amounts they previously held were as follows:

  • Greenhaven: 5,482,694 Rights
  • Kepos: 579,950 Rights
  • Yakira: 419,299 Rights

That totals 6,481,943 Rights, so at a maximum, there were really only 8,391,313 Rights (of the 14,873,256) available for tendering.  And since we already know that 1,826,233 have tendered up to this point, there are (at a maximum) approximately 6,565,080 Rights left that can tender up to the new deadline of November 22nd, or 656,508 shares if converted.  That’s still a chunky number of Rights Shares, so it appears Gig is hoping to reduce that number even further (assuming Greenhaven, Kepos and Yakira weren’t able to purchase any additional Rights).

Lastly, the extended Tender Offer deadline of November 22, indicates a shareholder vote to complete their combination will not happen before then, but keep in mind that Gig’s deadline expires on December 6th, so a vote date should come quite quickly after the tender offer closes.

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved